l General Information |
Product Name | Tacedinaline |
General description | Tacedinaline is a selective class I HDAC inhibitor with IC50 of 0.9, 0.9, 1.2, and >20 μM for human HDAC 1, 2, 3, and 8, respectively. |
Synonym | CI994, PD-123654, GOE-5549, Acetyldinaline, 4-acetamido-N-(2-aminophenyl)benzamide |
Purity | ≥98.0%(HPLC) | CAS Number | 112522-64-2 |
Formula | C15H15N3O2 | Molecular Weight | 269.304 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to off-white Solid |
Solubility(25°C) | DMSO | ≥45mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Tacedinaline is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by the induction of differentiation, the inhibition of cell proliferation, and apoptosis in susceptible tumor cell populations. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
